Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED NOVEMBER 2017. Refer to TA486: Aflibercept for treating choroidal neovascularisation for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | aflibercept (Eylea®) | ||
| Formulation | 40 mg/ml intravitreal injection | ||
| Reference number | 1586 | ||
| Indication | Treatment of adult patients with visual impairment due to myopic choroidal neovascularisation |
||
| Company | Bayer Healthcare Pharmaceuticals | ||
| BNF chapter | Eye | ||
| Submission type | Full | ||
| Status | Superseded | ||
| Advice number | 0117 | ||
| NMG meeting date | 11/01/2017 | ||
| AWMSG meeting date | 15/02/2017 | ||
| Date of issue | 14/03/2017 | ||
| NICE guidance | TA486: Aflibercept for treating choroidal neovascularisation (external website - opens in new window) |
||